EZH2 and neoplasm: Targeted selective inhibition of EZH2 with tazemetostat upregulates the expression of HLA class I molecules in anti-PD-1-resistant HNSCC cell lines and mouse models and increases antigen-specific CD8+ T cell proliferation, IFN-gamma production, CXCL10 expression, and tumor cell cytotoxicity [9].